TGFB1 and idiopathic pulmonary fibrosis: The related FDA-approved Class I inhibitor romidepsin indicated the very same effects, in addition to its profound capability in downregulating the protein expression of lysyl oxidase (LOX), an enzyme involved in collagen-crosslinking, in TGF-β-treated IPF fibroblasts.